Silo Pharma, Inc. (SILO) Stock Price & Analysis

Silo Pharma, Inc. (SILO) rose 3.19% to USD 6.46 as of June 10, 2026 at 03:42 UTC, according to Nexqual real-time market data.

SILO last closed at USD 6.26; the session ranged USD 6.12–6.7 on volume of 16,601 shares. Market capitalization is $7.01M, with a 52-week range of USD 3.32–15.15 (NCM). Source: Nexqual, June 10, 2026 at 03:42 UTC.

Key Statistics (as of June 10, 2026 at 03:42 UTC)

Technical Analysis (SILO)

Nexqual's technical model rates SILO "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:42 UTC.

Analyst Ratings (SILO)

Wall Street analysts rate SILO "None", per Nexqual as of June 10, 2026 at 03:42 UTC.

Earnings (SILO)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:42 UTC.

Financials & Fundamentals (SILO)

Source: Nexqual, June 10, 2026 at 03:42 UTC.

Financial Health Score (SILO)

Nexqual rates Silo Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:42 UTC.

Ownership (SILO)

Source: Nexqual, June 10, 2026 at 03:42 UTC.

Leadership (SILO)

Silo Pharma, Inc. is led by Eric Weisblum (age 55), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 03:42 UTC.

Major Backers & Investors (SILO)

Notable institutional backers of Silo Pharma, Inc. include AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, according to Nexqual as of June 10, 2026 at 03:42 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 03:42 UTC.

From Silo Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   Fibromyalgia affects approximately 4 million U.S. adults (2% of the population).
• Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents.
• In addition, we have established business procedures designed to maintain the confidentiality of our proprietary information, including the use of confidentiality agreements with employees, independent contractors, consultants and entities with which we conduct business.   To date, the intellectual property owned and licensed by us includes 5 issued patents and 20 pending patent applications in 14 patent families in the U.S. and abroad.

Partnerships

• SPC-14 was developed under a sponsored research agreement with Columbia University See "Investigator-Sponsored Study Agreements between the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer's and Depression Disorders." We have exclusive global rights to develop and commercialize SPC-14, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.
• We are actively collaborating with Columbia University, holding exclusive global rights to develop and commercialize SPC-15, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:42 UTC. This page is informational and not investment advice.